Connect with us

Hi, what are you looking for?

Tech

Glowing dye helps doctors find more prostate cancer cells during surgery, says University of Oxford

A glowing dye that sticks to cancer cells gives surgeons a “second pair of eyes”, according to experts at the University of Oxford.

The dye clings to prostate cancer cells and then starts glowing when illuminated during surgery.

This means doctors can remove more of the cancer during the operation and reduces the chance of it coming back.

Although the dye currently identifies prostate cancer, it could be adapted for other forms of the disease.

“With this technique, we can strip all the cancer away, including the cells that have spread from the tumour – which could give it the chance to come back later,” said surgery professor Freddie Hamdy from the University of Oxford. He was the lead author of the study into the dye.

“It also allows us to preserve as much of the healthy structures around the prostate as we can, to reduce unnecessary life-changing side-effects like incontinence and erectile dysfunction.”

Full clinical trials are under way to find out if surgery with the marker dye removes more prostate cancer and preserves more healthy tissue than existing surgical techniques, according to Cancer Research UK.

In an initial study, 23 men with prostate cancer were injected with the dye before undergoing surgery to remove their prostates.

The fluorescent dye showed the cancer cells and where they had spread into other tissues, such as the pelvis and lymph nodes.

A special imaging system shone a light on the prostate and nearby regions, making the cancer cells glow.

David Butler, 77, was one of those who took part in the study after tests showed his prostate cancer had begun to spread.

“I retired early to make the most of life’s pleasures, gardening, playing bowls and walking,” he said.

“Taking part in the Promote study has allowed me to have many more of those pleasures for years to come.”

He is now cancer-free.

The research was funded by Cancer Research UK and supported by Oxford’s Nuffield Department of Surgical Sciences, Department of Oncology and the National Institute for Health and Care Research biomedical research centre.

The work has been published in the European Journal of Nuclear Medicine and Molecular Imaging.

This post appeared first on sky.com

    You May Also Like

    Stocks

    In this episode of StockCharts TV‘s The MEM Edge, Mary Ellen reviews what’s shaping up in the broader markets after the Fed announced their rate cut...

    Tech

    Consumer rights group Which? is suing Apple for £3bn over the way it deploys the iCloud. If the lawsuit succeeds, around 40 million Apple...

    Tech

    Battle lines have been drawn between the almost 200 countries meeting in Azerbaijan as they seek to agree a new pot of money to...

    Tech

    Meta has lowered the minimum age to use the popular messaging platform WhatsApp. The move, which came into effect on Thursday, reduces the age...

    Disclaimer: globalwashingtonwebinar.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 globalwashingtonwebinar.com | All Rights Reserved